Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2023 02:58 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY

HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000...
July 14, 2023 08:33 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Christel Elise Kanli, primary insider and CFO/COO in Hofseth BioCare ASA («HBC») has today purchased 74,000 shares in HBC at an average price of approx. NOK 2.70 per share. As a result of the...
May 30, 2023 02:40 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer...
May 15, 2023 01:50 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SPIN-OFF OF PROSTATE CANCER CO-TREATMENT PROJECT

Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project") to a new US entity to be called HBC Immunology Inc....
May 12, 2023 01:56 ET | Source: Hofseth Biocare ASA

Hofseth BioCare ASA: FIRST QUARTER 2023 FINANCIAL REPORT

The first quarter of 2023 shows a very good development for HBC. Revenues came in at NOK 44m vs NOK 30m last year, a growth of 48 % YoY and 32 % QoQ. The underlying growth we are seeing is coming from...
April 28, 2023 08:09 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: COMPLETED ANNUAL GENERAL MEETING

Hofseth BioCare ASA held its Annual General Meeting on 28 April 2023. 253,351,609 shares, amounting to 64.13 per cent of the share capital, were represent in the meeting or by proxy. All proposals...
April 28, 2023 05:32 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: DISCLOSURE OF VOTING PROXIES

Reference is made to the notice from Hofseth BioCare ASA (the "Company") for an annual general meeting to be held on 28 April 2023 (the "AGM"). Torill Standal Eliassen, board member of the Company,...
April 13, 2023 17:56 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2023

The Annual General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 28 April 2023 at 13:00 CET. The notice of the Annual General Meeting...
March 31, 2023 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC ANNUAL REPORT 2022

The Board of Directors of Hofseth BioCare ASA (“HBC”) has approved the financial statements for 2022 and the Company has today published the Annual Report and Sustainability Report for 2022. Please...
February 28, 2023 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at...